key: cord-0806510-aigdcfac
authors: Vesin, Benjamin; Lopez, Jodie; Noirat, Amandine; Authié, Pierre; Fert, Ingrid; Le Chevalier, Fabien; Moncoq, Fanny; Nemirov, Kirill; Blanc, Catherine; Planchais, Cyril; Mouquet, Hugo; Guinet, Françoise; Hardy, David; Vives, Francina Langa; Gerke, Christiane; Anna, François; Bourgine, Maryline; Majlessi, Laleh; Charneau, Pierre
title: An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
date: 2022-04-27
journal: Mol Ther
DOI: 10.1016/j.ymthe.2022.04.016
sha: 48c15e3c0c606cd162b67ac56ef3e39d30a4d38d
doc_id: 806510
cord_uid: aigdcfac

As the COVID-19 pandemic continues and new SARS-CoV-2 variants of concern emerge, the adaptive immunity initially induced by the first-generation COVID-19 vaccines starts waning and needs to be strengthened and broadened in specificity. Vaccination by the nasal route induces mucosal, humoral and cellular immunity at the entry point of SARS-CoV-2 into the host organism and has been shown to be the most effective for reducing viral transmission. The lentiviral vaccination vector (LV) is particularly suitable for this route of immunization due to its non-cytopathic, non-replicative and scarcely inflammatory properties. Here, to set up an optimized cross-protective intranasal booster against COVID-19, we generated an LV encoding stabilized Spike of SARS-CoV-2 Beta variant (LV::SBeta-2P). mRNA vaccine-primed and -boosted mice, with waning primary humoral immunity at 4 months post-vaccination, were boosted intranasally with LV::SBeta-2P. Strong boost effect was detected on cross-sero-neutralizing activity and systemic T-cell immunity. In addition, mucosal anti-Spike IgG and IgA, lung resident B cells, and effector memory and resident T cells were efficiently induced, correlating with complete pulmonary protection against the SARS-CoV-2 Delta variant, demonstrating the suitability of the LV::SBeta-2P vaccine candidate as an intranasal booster against COVID-19. LV::SBeta-2P vaccination was also fully protective against Omicron infection of the lungs and central nervous system, in the highly susceptible B6.K18-hACE2IP-THV transgenic mice.

Considering: (i) the sustained pandemicity of coronavirus disease 2019 (COVID-19), (ii) 48 weakening protection potential of the first-generation vaccines against Severe Acute Respiratory 49 Syndrome beta-coronavirus 2 (SARS-CoV-2), and (iii) the ceaseless emergence of new viral Variants 50 of Concerns (VOCs), new effective vaccine platforms can be critical for future primary or booster 51

vaccines. 1 We recently demonstrated the strong performance of a non-integrative lentiviral 52 vaccination vector (LV) encoding the full-length sequence of Spike glycoprotein (S) from the 53 ancestral SARS-CoV-2 (LV::S), when used in systemic prime followed by intranasal (i.n.) boost in 54 multiple preclinical models. 2 LV::S ensures complete (cross) protection of the respiratory tract 55 against ancestral SARS-CoV-2 and VOCs. 3 In addition, in our new transgenic mice expressing human 56

Angiotensin Converting Enzyme 2 (hACE2) and displaying unprecedented permissiveness of the 57 brain to SARS-CoV-2 replication, an i.n. boost with LV::S is required for full protection of the central 58 nervous system. 3 LV::S is intended to be used as a booster for individuals who already have been 59 vaccinated against and/or infected by SARS-CoV-2, to reinforce and broaden protection against 60 emerging VOCs with immune evasion potential. 4 

Vaccine LVs are non-integrating, non-replicative, non-cytopathic and negligibly inflammatory. 5,6 62 These vectors are pseudotyped with the heterologous glycoprotein from Vesicular Stomatitis Virus 63 (VSV-G) which confers them a broad tropism for various cell types, including dendritic cells. The 64 latter are mainly non-dividing cells and thus usually hardly permissive to gene transfer. However, 65

LVs possess the crucial ability to efficiently transfer genes to the nuclei of not only dividing but also 66 non-dividing cells, therefore making efficient transduction of non-dividing immature dendritic cells 67 possible. The resulting endogenous antigen expression in dendritic cells, with their unique ability to 68 activate naïve T cells, 7 correlates with a strong induction of high-quality effector and memory T 69 cells. 8 Importantly, the VSV-G pseudo-typing of LVs prevents them from being targets of preexisting 70 against distinct VOCs. Despite high vaccination rates, the current exacerbation of the world-wide 83 pandemic indicates that repeated booster immunizations will be needed to ensure individual and 84 collective immunity against COVID-19. In this context, the safety and potential adverse effects of 85 multiple additional homologous doses of the first generation COVID-19 vaccines, for instance related 86 to allergic reaction to polyethylene glycol (PEG) contained in mRNA vaccines, have to be 87 considered. 13 Importantly, a heterologous prime-boost vaccine delivery method has been proven to 88 be a more successful strategy than the homologous prime-boost approach in numerous preclinical 89 models of various infectious diseases. 14-16 Therefore, new efficient vaccination platforms are of 90 particular interest to develop heterologous boosters against COVID-19. The LV::S vaccine candidate 91 has potential for prophylactic use against COVID-19, mainly based on its powerful capacity to induce 92 not only strong neutralizing humoral responses, but also and most importantly, robust protective T-93 cell responses which preserve their immune detection of spike from SARS-CoV-2 VOCs, despite the 94 accumulation of escape mutations. 3 The basis for the immunogenicity of LVs is usually the genetic 95 message they deliver to host cells and that encodes the targeted antigen. However, in the particular 96 case of viral envelope proteins used as antigens, that comprise the transmembrane and the tail 97 segments, it cannot be excluded that the LV is pseudotyped by both VSV-G and the viral envelope 98 protein they encode. In the context of LV::SFL, the possible Spike glycoprotein on the LV surface 99 may contribute to the induction of immune responses, in addition to the genetic message which is 100 translated and expressed by the antigen presenting cells. LV::S is remarkably suited to be used, as a 101 heterologous i.n. booster vaccine, to reinforce and broaden protection against the emerging VOCs, 102 while collective immunity in early vaccinated nations is waning a few months after completion of the 103 initial immunizations, and while new waves of infections are on the rise. 4 104 cells in H-2 b mice. 2 Importantly, the weak anti-S CD8 + T-cell immunity, detectable in the spleens 180 of mRNA-primed-boosted mice at wk 17, largely increased following i.n. boost with 1 × 10 8 and 1 181 × 10 9 TU of LV::SBeta-2P, similarly to the increase after i.m. mRNA boost (Figure 4) . 182

In parallel, in the same animals, the mucosal anti-SCoV-2 T-cell immunity was assessed by The LV-based strategy, is highly efficient, not only in inducing humoral responses but also, and 270 particularly, in establishing high quality and memory T-cell responses. 8 This makes it a suitable 271 platform for a heterologous boost, even if it is also largely efficacious on its own as a primary COVID-272 19 vaccine candidate. 2,3 Furthermore, LVs are non-cytopathic, non-replicative and scarcely 273 inflammatory. They can thus be used to perform non-invasive i.n. boost to efficiently induce 274 sterilizing mucosal immunity, which protects the respiratory system as well as the central nervous 

Boosting immunity to COVID-19 vaccines

Immunization delivered by lentiviral vectors for cancer and infectious 519 diseases

Use of lentiviral vectors in vaccination

Origin and development 523 of classical dendritic cells

Lentiviral vector induces high-quality memory T cells via dendritic cells transduction

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment 528 in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART)

Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the 532 Induction of STING-Independent CD8(+) T Cell Responses

Scent of a vaccine

Intranasal ChAdOx1 nCoV-19/AZD1222 537 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

Maintaining Safety with SARS-CoV-2 Vaccines

Heterologous 542 prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates

Heterologous prime-boost vaccination

Effectiveness of heterologous ChAdOx1 nCoV-19 and 547 mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Immune responses 581 against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Prime-boost vaccine strategy against viral infections: 584 Mechanisms and benefits

Adaptive immunity to SARS-CoV-2 and COVID-19

A single intranasal or intramuscular immunization with 589 chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

A single intranasal dose of chimpanzee adenovirus-593 vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques

Cross-Reactive Neutralizing Antibody 597 Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

SARS-CoV-2 Beta variant infection elicits potent lineage-601 specific and cross-reactive antibodies

Human nasal immune system: a 604 special site for immune response establishment

A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles 607

Elicits Broad Neutralizing Antibody Response in Pigs

Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian 611 immunodeficiency virus SIVmac251 challenge in macaques

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 614 neutralization

LV::SGamma and (cross) sero-neutralization assays in C57BL/6 mice (n = 4-5/group). (B) EC50 of 622 neutralizing activity of sera from vaccinated mice was evaluated before and after the boost, against 623 pseudo-viruses carrying SCoV-2 from D614G, Alpha, Beta or Gamma variants

C57BL/6 mice, vaccinated following the regimen detailed in (A) with LV encoding for SD614G, either 625 WT or carrying the K 986 P -V 987 P substitutions in the S2 domain

Anti-SCoV-2 humoral responses in mRNA-vaccinated mice which were further 628 intranasally boosted with LV::SBeta-2P (A) Timeline of mRNA i.m.-i.m. prime-boost vaccination in

C57BL/6 mice which were later immunized i.n. by escalating doses of LV::SBeta-2P (n = 4-5/group) 630 and the (cross) sero-neutralization follow-up. (B) Serum EC50 determined at the indicated time points 631 against pseudo-viruses carrying SCoV-2 from D614G

Anti-SCoV-2 IgG (upper panel) or IgA (lower panel) titers in the sera two weeks after i

001). (D) Sera EC50, after the late boost given at wk 15, and as determined at wk 17. £ = 635 not determined

Lung B-cell resident memory subset in mRNA-vaccinated mice which were further 637 intranasally boosted with LV::SBeta-2P. The mice are those detailed in the Figure 2. Mucosal immune 638 cells were studied two weeks after LV::SBeta-2P i.n. boost. (A) Cytometric gating strategy to detect 639 lung Brm in mRNA-vaccinated mice which were further intranasally boosted with LV

Percentages of these cells among lung CD19 + surface IgM -/IgD -B cells in mRNA-vaccinated mice 641 which were further intranasally boosted with LV

test (*= p < 0.05). cells were studied two weeks after LV::SBeta-2P i.n. boost. (A) Cytometric gating strategy to detect 657 lung CD8 + T resident memory (CD44 + CD69 + CD103 + ), and (B) percentages of this subset among

CD8 + CD44 + T-cells in mRNA-vaccinated mice which were further intranasally boosted with 659 LV::SBeta-2P. Statistical significance was evaluated by Mann-Whitney test (*= p < 0.05)

Full protective capacity of LV::SBeta-2P i.n. boost against Delta variant in initially 661 mRNA-primed and boosted mice. (A) Timeline of mRNA i.m.-i.m. prime-boost vaccination in

C57BL/6 mice which were later immunized i.n. with 1 × 10 8 TU/mouse of LV::SBeta-2P (n =

pre-treated i.n. with Ad5::hACE-2 4 days before i.n. challenge with 0.3 × 10 5 TCID50 of

Comparative quantification of hACE-2 mRNA in the lungs of 665 Ad5::hACE-2 pre-treated mice at 3 dpi. (C) Lung viral RNA contents, evaluated by conventional E-666 specific (top) or sub-genomic Esg-specific (bottom) qRT-PCR at 3 dpi. Red lines indicate the 667 detection limits. Statistical significance was evaluated by Mann-Whitney test

Figure 8. Full protective capacity of LV::SBeta-2P used in a prime (i.m.) boost (i.n.) regimen

Timeline of prime-boost vaccination and i.n. challenge with 0.3 × 10 5 671 TCID50 of SARS-CoV-2 Omicron variant in B6.K18-hACE2 IP-THV transgenic mice (n = 5/group)

Lung viral RNA contents, evaluated by sub-genomic Esg-specific qRT-PCR at 5 dpi. Red lines 673 indicate the detection limits. Statistical significance was evaluated by Mann-Whitney test (*= p < 0